Communicating the CAR T-Cell Treatment Experience to Support Patient Decision Making in Multiple Myeloma

This segment focuses on how to introduce CAR T-cell therapy to patients with multiple myeloma who may hesitate because of concerns about toxicity, travel distance, or caregiver needs. Dr. Raje emphasizes that open, balanced conversations are essential and begins by explaining that the most significant toxicities, such as cytokine release syndrome or neurotoxicity, typically occur early and while patients are under close monitoring. She highlights that toxicity patterns today are more predictable and manageable than in the early years of CAR T use, which helps reassure patients. Clear explanations about logistics, including the need for caregiver support and temporary proximity to the treatment center, help set realistic expectations. Many centers provide resources such as housing assistance, financial support, social work services, and nurse navigators who guide families through each step. By presenting the process transparently, emphasizing both benefits and risks, and outlining available support systems, clinicians can help patients make informed and confident decisions about CAR T therapy.